Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: 2 | Rare Historical Photos

Asian shares are mixed after heavy selling of potential AI losers hits Wall Street

Shares are mixed in Asia after U.S. stocks slumped on heavy selling of shares in companies that could be losers in the artificial-intelligence boom

The Independent UK

Novo Nordisk Stock Is Deeply Oversold on Weight Loss Drug Fail. Should You Buy the Dip?

Novo Nordisk stock tanks as CagriSema appears inferior to Eli Lilly’s competing weight-loss drug in a late-stage trial. But NVO shares are still worth buying at current levels.

Barchart

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut

Investors had little time to celebrate Eli Lilly's huge post-earnings gain. While Hims & Hers Health knocked shares down, LLY remains a healthcare stalwart.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

TrumpRx is live. Here's what the website shows

The site is a key part of President Trump's efforts to lower health costs but isn't expected to significantly affect drug prices.

Axios

The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles

Eli Lilly surges past the trillion-dollar mark as aggressive manufacturing expansion drives volume growth that eclipses rival Novo Nordisk in 2026.

MarketBeat

New weight loss drug by Pfizer shows promising results in trial

Pfizer acquired the drug’s developer following a bidding war with Novo Nordisk last year

The Independent UK

Novo Nordisk shares plunge on outlook warning as Mounjaro rival races ahead

Wegovy and Ozempic maker Novo Nordisk forecast plunging sales and earnings in 2026, which saw the Danish drugmaker’s shares plummet by nearly a fifth.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition

The Guardian - UK

Eli Lilly Stock Outlook: Is Wall Street Bullish or Bearish?

Eli Lilly has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.

Barchart

Why Denmark can't use Ozempic as a trump card with the US in Greenland talks

Novo Nordisk, the Danish manufacturer of weight-loss drugs Ozempic and Wegovy, has a large market share in the US. But it's not enough to put pressure on US President Donald Trump's administration during Greenland talks, experts say.

Euronews

Commodity Volatility, Earnings and Other Key Things to Watch

Markets enter February following a volatile final trading day of January that saw investors grappling with hotter-than-expected inflation data alongside news of a new Federal Reserve chair nominee.

Barchart

Drugmaker Eli Lilly announces new plant in Pennsylvania as part of broader domestic expansion

Drugmaker Eli Lilly and Co. says it'll build a $3.5 billion manufacturing facility in Pennsylvania, as the company expands domestic production and capitalizes on surging sales of obesity and diabetes treatments

The Independent UK

Eye-stroke, vomiting and burst colon: Lawsuits accuse weight-loss drugs of severe side effects

Thousands of patients have filed lawsuits against drug producers claiming side effects - but the companies insist their products are properly tested

The Independent UK

Fake weight-loss medication in tablet form could flood Britain, experts warn

Better regulation and enforcement urged before launch of oral treatments, which criminals are likely to try to exploit

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

The Independent UK

Takeaways from the AP's report on turmoil surrounding the FDA's new fast-track drug program

Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on drugs cleared under a new plan to slash FDA drug review times

The Independent UK

Legal questions swirl around FDA's new expedited drug program, including who should sign off

A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been rocked by recent layoffs and resignations

MarketBeat

A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition of Ventyx Biosciences.

The Independent UK

Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their blockbuster weight-loss drugs

Barchart

What to Expect From Eli Lilly’s Q4 2025 Earnings Report

Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.

The Independent UK

New fleet of weight loss drugs are more effective than the current popular obesity medications at trial

One in eight Americans are taking a GLP-1 drug, a recent poll found

MarketBeat

This NVIDIA Partnership Shows How Big AI Can Really Get

NVIDIA is well-positioned to dominate AI markets across industries and verticals for years to come; analysts point to a 40% upside.

The Independent UK

Amazon starts to offer Wegovy weight loss pill to customers

The new oral Wegovy, launched this week, contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic

MarketBeat

Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.